Drug: KVD900 300 mg clinical trials

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

This study is for young people aged 12-17 with hereditary angioedema (HAE) types 1 or 2 who are already in another KVD900 study. It looks at how the body handles the medicine KVD900 to make sure we understand it better for this age group.